Publisert 2022

Les på engelsk


Tidsskrift : BMJ Open , vol. 12 , 2022

Internasjonale standardnummer :
Trykt : 2044-6055
Elektronisk : 2044-6055

Publikasjonstype : Vitenskapelig artikkel

Bidragsytere : Hjorth, Therese; Schadow, Alena; Revheim, Ingrid; Spielau, Ulrike; Thomassen, Lise Margrete; Meyer, Klara; Piotrowski, Katja; Rosendahl-Riise, Hanne; Rieder, Anne; Varela-Tomasco, Paula; Lysne, Vegard; Ballance, Simon; Koerner, Antje; Landberg, Rikard; Buyken, Anette E.; Dierkes, Jutta

Sak : 8


Kosthold og helse


Har du spørsmål om noe vedrørende publikasjonen, kan du kontakte Nofimas bibliotekleder.

Kjetil Aune


Introduction In 2012, the estimated global prevalence of pre-diabetes was 280 million, and the prevalence is expected to rise to 400 million by 2030. Oat-based foods are a good source of beta-glucans, which have been shown to lower postprandial blood glucose. Studies to evaluate the effectiveness of the long-term intake of beta-glucan- enriched bread as part of a habitual diet among individuals with pre-diabetes are needed. Therefore, we designed a multicentre intervention study in adults with pre-diabetes to investigate the effects of consumption of an oat-derived beta-glucan- enriched bread as part of a normal diet on glycated haemoglobin (HbA1c) in comparison to consumption of whole-grain wheat bread. Methods and analysis The CarbHealth trial is a multicentre double-blind randomised controlled 16-week dietary intervention trial in participants 40–70 years of age with a body mass index of ≥27 kg/m2 and HbA1c of 35–50 mmol/ mol. The study is conducted at four universities located in Norway, Sweden and Germany and uses intervention breads specifically designed for the trial by Nofima AS. The aim is to recruit 250 participants. The primary outcome is the difference in HbA1c between the intervention and the control groups. The main analysis will include intervention group, study centre and baseline HbA1c as independent variables in an analysis of covariance model. Ethics and dissemination The study protocol was approved by respective ethical authorities in participating countries. The results of the study will be communicated through publication in international scientific journals and presentations at (inter)national conferences. Trial registration number NCT04994327.


Temasider tilknyttet publikasjonen